TECH Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 14.91%. Bio-Techne Corp.'s return on equity of 3.85% beat Boston Scientific Corp.'s return on equity of 12.46%.

Bio-Techne Corp. has a consensus price target of $69.17, signalling upside risk potential of 12.14%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 29.7%. Given that Boston Scientific Corp. has higher upside potential than Bio-Techne Corp., analysts believe Boston Scientific Corp. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.52%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Bio-Techne Corp.'s net income of $38.2M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 126.08x while Boston Scientific Corp.'s PE ratio is 52.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.99x versus 7.52x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

CONMED Corp. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 0.84%. Bio-Techne Corp.'s return on equity of 3.85% beat CONMED Corp.'s return on equity of 6.56%.

Bio-Techne Corp. has a consensus price target of $69.17, signalling upside risk potential of 12.14%. On the other hand CONMED Corp. has an analysts' consensus of $52.80 which suggests that it could grow by 34.76%. Given that CONMED Corp. has higher upside potential than Bio-Techne Corp., analysts believe CONMED Corp. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison CONMED Corp. has a beta of 0.977, suggesting its less volatile than the S&P 500 by 2.326%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.52%. CONMED Corp. offers a yield of 2% to investors and pays a quarterly dividend of $0.20 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. CONMED Corp. pays out 18.82% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than CONMED Corp. quarterly revenues of $338.6M. Bio-Techne Corp.'s net income of $38.2M is higher than CONMED Corp.'s net income of $2.9M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 126.08x while CONMED Corp.'s PE ratio is 19.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.99x versus 0.93x for CONMED Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 21.32%. Bio-Techne Corp.'s return on equity of 3.85% beat Pfizer Inc.'s return on equity of 10.84%.

Bio-Techne Corp. has a consensus price target of $69.17, signalling upside risk potential of 12.14%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 11.56%. Given that Bio-Techne Corp. has higher upside potential than Pfizer Inc., analysts believe Bio-Techne Corp. is more attractive than Pfizer Inc..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.52%. Pfizer Inc. offers a yield of 6.61% to investors and pays a quarterly dividend of $0.43 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Bio-Techne Corp.'s net income of $38.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 126.08x while Pfizer Inc.'s PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.99x versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of 13.32% compared to Bio-Techne Corp.'s net margin of 6.76%. Bio-Techne Corp.'s return on equity of 3.85% beat Revvity, Inc.'s return on equity of 3.05%.

Bio-Techne Corp. has a consensus price target of $69.17, signalling upside risk potential of 12.14%. On the other hand Revvity, Inc. has an analysts' consensus of $113.67 which suggests that it could grow by 12.78%. Given that Revvity, Inc. has higher upside potential than Bio-Techne Corp., analysts believe Revvity, Inc. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.464, which suggesting that the stock is 46.414% more volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.059, suggesting its more volatile than the S&P 500 by 5.937%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.52%. Revvity, Inc. offers a yield of 0.28% to investors and pays a quarterly dividend of $0.07 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Revvity, Inc. pays out 11.63% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $286.6M, which are smaller than Revvity, Inc. quarterly revenues of $698.9M. Bio-Techne Corp.'s net income of $38.2M is lower than Revvity, Inc.'s net income of $47.2M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 126.08x while Revvity, Inc.'s PE ratio is 50.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.99x versus 4.25x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.